Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market: Industry Analysis and Forecast (2024-2030)

  • Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market size was valued at US$ 610.24 Mn. in 2023 and the total revenue is expected to grow at 6.5 % through 2024 to 2030, reaching nearly US$ 948.3 Mn. by 2030.

  • Format : PDF | Report ID : SMR_736

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Definition/Overview:

Asia-Pacific is projected to grow during the forecast period at a significant rate. The rising incidence of cancer, large investments in new ERCP technology by hospitals, research centres and a significant focus on research activities to improve endoscopic techniques are all important factors that are fuelling the growth of Endoscopic Retrograde Cholangiopancreatography Market. Asia-Pacific also has presence of key players in its region which emphasizes the importance of Endoscopic Retrograde Cholangiopancreatography Market and functions as a major driver.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Dynamics:

The Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market is growing due to the rising prevalence of pancreatic and biliary illnesses, the existence of a large number of participants in the market, and the development of improved technology-based devices. From 2024 to 2030, the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market is expected to grow at a CAGR of 6.5 %, from USD 447 million in 2022 to USD 479 million in 2027. Endoscopic Retrograde Cholangiopancreatography allows surgeons to operate on more vulnerable patients, such as the elderly, and treat more difficult illnesses, such as cancer.

 

Endoscopic Retrograde Cholangiopancreatography has a number of advantages, including reduced postoperative discomfort and complications, quicker recovery after the operation, less sedation, and a shorter hospital stays those results is cost saving on hospital charges. Minimally invasive procedures have been developed in surgery, interventional radiology, and advanced endoscopy to effectively treat numerous diseases and improve postoperative results of patients. Operating room-ready wireless endoscopes are also now available on the market. ScoutCam, a developer of bespoke visual solutions, has incorporated its wireless mini ScoutCam with medical endoscopic devices in May 2020 and showcased the results for everyone to review.

 

The demand for Endoscopic Retrograde Cholangiopancreatography equipment in the APAC area has increased due to greater awareness of less invasive procedures among the senior population and the rising frequency of chronic conditions. Furthermore, the APAC endoscopy devices market is projected to grow as a result of rising demand for endoscopes for treatment and diagnostics, as well as technological advancements leading to improved applications. Infections acquired through non-sterilized endoscopes are potentially a danger to the market's growth.

 

Factors such as an increase in the number of hospitals, higher patient demand for less invasive treatments, technological advancements, and an increase in the older population are likely to drive the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market growth. Additionally, as per report published in Department of Community Medicine, Mumbai lot of people are suffering from Irritable bowel syndrome (IBS) which is a functional condition of the gastrointestinal tract without any associated structural impairment in which normal bowel action is exaggerated or distorted, resulting in constipation, diarrhoea, and usually stomach pain or discomfort. It's also known as a brain–gut axis dysregulation that interacts with visceral hypersensitivity and is linked to digestive motor abnormalities, microinflammation of the gut, and maybe an imbalance of the intestinal bio flora. These ailments can be diagnosed with the help of Endoscopic Retrograde Cholangiopancreatography which can help the market grow during the forecast period.

 

Furthermore, the usage of alternative endoscopic equipment is increasing, as is the adoption and awareness of therapy and diagnostics. Furthermore, during the forecast period, the rising prevalence of gastrointestinal illnesses is predicted to increase the endoscopic devices market. Furthermore, market growth is likely to quicken as the senior population grows. The endoscope market is being stifled by the high cost of medical devices and diagnostics. Furthermore, strict regulatory norms for new technical goods have hampered the market's expansion.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography

 

To get more Insights: Request Free Sample Report

 

The Asia-Pacific region, with a focus on India, China, and Japan, is expected to have the greatest growth rate in the Endoscopic Retrograde Cholangiopancreatography market in the approaching years amongst other countries in the APAC region. Administrative spending in launching new endoscopic units in India and government and venture capital investments in China can be attributed to the strong growth in India and China. Indonesia, Vietnam, and Malaysia are also key players in the APAC region. The Indian Endoscopic Retrograde Cholangiopancreatography market is expected to account for a large part of the APAC market during the forecast period. The Indian market becomes more appealing as the population grows and the standard of living rises, more companies would be inclined to invest and operate there. In cases of chronic stomach irritation, a gastrointestinal endoscopy is advantageous. Furthermore, as India's population expands, so will the number of gastrointestinal diseases reported, driving the Endoscopic Retrograde Cholangiopancreatography market upwards.

 

According to the November 2018 study, A study of the prevalence and aetiology of irritable bowel syndrome in an urban slum community in Mumbai, the prevalence of irritable bowel syndrome was 12.27 percent, with 56 percent of males and 44 percent of women suffering from the condition. Countries like China, Japan, and Australia, on the other hand, are expected to develop at CAGRs of 6.5 percent, 4.5 percent, and 6.2 percent, respectively. Imaging and modest surgical procedures are performed using endoscopic methods. Due to a growing need for less invasive procedures, increased use of endoscopy for treatment and diagnostics, and technological advancements leading in enhanced applications, the market is predicted to develop.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Segment Analysis:

On the basis of product type, Endotherapy devices are projected to dominate the market in 2030 due to growth of gastrointestinal conditions and minimally invasive surgeries. Additionally, the reason for significant growth in the Asia-Pacific region is due to intense expenditure in healthcare sector that is fuelling the growth of ERCP market in the region.

 

On the basis of end user, the Endoscopic Retrograde Cholangiopancreatography Market in Asia-Pacific is dominated by hospitals and clinics. This is largely due to the fact that majority of volume consumption comes from hospital and clinics across the Asia-Pacific region. The testing and diagnosis are also mostly in-house when it comes to hospitals in the Asia-Pacific region. All these factors contribute significantly to the growth of Endoscopic Retrograde Cholangiopancreatography Market.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography

 

On the basis of application, Pancreatic Sphincterotomy is projected to dominate the Endoscopic Retrograde Cholangiopancreatography Market due to prevalence of IBS (irritable bowel syndrome) amongst the Asia-Pacific Population. Additionally, the growing geriatric population in the Asia-Pacific region has a demand for endoscopies due to increase in biliary disorders.    

 

The objective of the report is to present a comprehensive analysis of the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market to the stakeholders in the industry. The report provides trends that are most dominant in the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.

 

The qualitative and quantitative data provided in the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market

 

The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market. The report also analyses if the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.

 

The report also includes a PESTEL Analysis, which aids in the development of company strategies. Political variables help in figuring out how much a government can influence the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market. Economic variables aid in the analysis of economic performance drivers that have an impact on the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market. Understanding the impact of the surrounding environment and the influence of environmental concerns on the Asia-Pacific Endoscopic Retrograde Cholangiopancreatography market is aided by legal factors.

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Scope:

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market

Market Size in 2023

USD 610.24 Mn.

Market Size in 2030

USD 948.31Mn.

CAGR (2024-2030)

6.5%

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

Segment Scope

By Product Type

  • Endoscopes
  • Endotherapy Devices
  • Imaging Devices
  • Energy Devices

By Application

  • Biliary Sphincterotomy
  • Biliary Dilatation
  • Biliary Stenting
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Dilatation
  • Pancreatic Duct Stenting

By End-user

  • Hospitals & Clinics
  • Ambulatory Surgery Centers
  • Others

Country Scope

China
India 
Japan 
South Korea
Australia 
ASEAN
Rest of APAC

 

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Key Players:  

  • Fujifilm Holding Corporation (Japan)
  • Advin Healthcare (India)
  • Smith+Nephew Pte Ltd (Singapore)
  • Stellis Japan Co. Ltd (Japan)
  • Accellent (Malaysia)
  • Bard Singapore Pte. Ltd. (Singapore)
  • Conmed Corporation (India)
  • Olympus Corporation (Japan)
  • KARL STORZ Endoscopy Asia Marketing Pte. Ltd (Singapore)
  • William A. Cook Australia PTY (Australia)
  • B. Braun Medical (India)


CHOOSE LICENSE TYPE


Single User - $2600

Corporate User - $3300

Frequently Asked Questions

1.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market: Research Methodology
1.1    Research Data 
1.1.1.    Primary Data
1.1.2.    Secondary Data

1.2.    Market Size Estimation
1.2.1.    Bottom-Up Approach
1.2.2.    Top-Up Approach

1.3.    Market Breakdown and Data Triangulation
1.4.    Research Assumption

2.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Executive Summary
2.1.    Market Overview
2.2.    Market Size (2023) and Forecast (2024 – 2030) and Y-O-Y%
2.3.    Market Size (USD) and Market Share (%) – By Segments 

3.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market: Competitive Landscape
3.1.    SMR Competition Matrix
3.2.    Key Players Benchmarking
3.2.1.    Company Name
3.2.2.    Headquarter
3.2.3.    Business Segment
3.2.4.    End-user Segment
3.2.5.    Y-O-Y%
3.2.6.    Revenue (2023)
3.2.7.    Company Locations

3.3.    Market Structure
3.3.1.    Market Leaders 
3.3.2.    Market Followers
3.3.3.    Emerging Players

3.4.    Consolidation of the Market

4.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market: Dynamics
4.1.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Trends 
4.2.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Drivers
4.3.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Restraints
4.4.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Opportunities
4.5.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Challenges
4.6.    PORTER’s Five Forces Analysis
4.7.    PESTLE Analysis
4.8.    Technological Analysis
4.8.1.    Artificial Intelligence In GI Endoscopy
4.8.2.    Single-Use Endoscopes
4.8.3.    Technological Roadmap

4.9.    Regulatory Landscape 

5.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market: Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2030)
5.1.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Size and Forecast, by Product Type (2024-2030)
5.1.1.    Endoscopes
5.1.2.    Endotherapy Devices
5.1.3.    Imaging Devices
5.1.4.    Energy Devices

5.2.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Size and Forecast, by Application (2024-2030)
5.2.1.    Biliary Sphincterotomy
5.2.2.    Biliary Dilatation
5.2.3.    Biliary Stenting
5.2.4.    Pancreatic Sphincterotomy
5.2.5.    Pancreatic Duct Dilatation
5.2.6.    Pancreatic Duct Stenting

5.3.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Size and Forecast, by End-User (2024-2030)
5.3.1.    Biliary Sphincterotomy
5.3.2.    Biliary Dilatation
5.3.3.    Biliary Stenting
5.3.4.    Pancreatic Sphincterotomy
5.3.5.    Pancreatic Duct Dilatation
5.3.6.    Pancreatic Duct Stenting

5.4.    Asia-Pacific Endoscopic Retrograde Cholangiopancreatography Market Size and Forecast, by Country (2024-2030)
5.4.1.    China
5.4.2.    India 
5.4.3.    Japan 
5.4.4.    South Korea
5.4.5.    Australia 
5.4.6.    ASEAN
5.4.7.    Rest of APAC

6.    Company Profile: Key Players
6.1.    Fujifilm Holding Corporation (Japan)
6.1.1.    Company Overview
6.1.2.    Business Portfolio
6.1.3.    Financial Overview
6.1.4.    SWOT Analysis
6.1.5.    Strategic Analysis
6.1.6.    Recent Developments

6.2.    Advin Healthcare (India)
6.3.    Smith+Nephew Pte Ltd (Singapore)
6.4.    Stellis Japan Co. Ltd (Japan)
6.5.    Accellent (Malaysia)
6.6.    Bard Singapore Pte. Ltd. (Singapore)
6.7.    Conmed Corporation (India)
6.8.    Olympus Corporation (Japan)
6.9.    KARL STORZ Endoscopy Asia Marketing Pte. Ltd (Singapore)
6.10.    William A. Cook Australia PTY (Australia)
6.11.    B. Braun Medical (India)

7.    Key Findings 

8.    Analyst Recommendations
8.1.    Strategic Recommendations 
8.2.    Future Outlook

Enquiry Before Buy


Request Sample PDF